Navigation Links
Hyam Levitsky Joins Roche as Head of Cancer Immunology Experimental Medicine
Date:10/17/2011

NUTLEY, N.J., Oct. 17, 2011 /PRNewswire/ -- Roche is pleased to announce the appointment of Hyam Levitsky, MD, as Head of Cancer Immunology Experimental Medicine, effective September 1. Levitsky joined Roche from The Johns Hopkins University School of Medicine, where he has been Professor of Oncology, Medicine and Urology and an active staff member in Oncology and Medicine at The Johns Hopkins Hospital since 2002.

In this new role, within the Pharma Research and Early Development (pRED) organization, Levitsky will be responsible for guiding research and early development programs focused on the immunotherapy of cancer, overseeing experimental medicine studies and projects in collaboration with internal or external partners. He will also be involved in the selection and validation of targets and clinical candidate selection as well as establishing strong alliances and partnerships with leading research and academic institutions. As part of this effort, he will continue to hold an academic appointment at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center where he will maintain his ongoing research program.

"Hy is recognized in the cancer immunotherapy community for his many contributions that include basic discoveries in antigen processing and presentation, T cell tolerance, lymphocyte homeostasis, vaccine development, and novel molecular imaging of anti-tumor immunity," said Michael Burgess, MD, PhD, Global Head, Oncology Discovery and Translational Area. "With his extensive and wide-ranging academic and medical research background, we believe he is uniquely qualified to bring new and different perspectives to the pRED Oncology organization and look forward to utilizing his expertise to develop differentiated cancer medicines that are beneficial for patients and healthcare providers."

"The time has never been better to see the advances in our understanding of the immune response to cancer translate into effective new treatments for patients," said Levitsky. "Roche has made an extraordinary investment in technologies that enable an unprecedented level of control of the anti-tumor immune response. Having the opportunity to lead these efforts between Roche and its research and academic partners is a dream come true."

After receiving his BS degree from the University of Pennsylvania School of Engineering and Applied Science, Levitsky earned his MD at Johns Hopkins School of Medicine and did his internship and residency in Internal Medicine on the Osler Medical Service at Johns Hopkins Hospital, rising to become Assistant Chief of Service. He trained in Medical Oncology as a Senior Clinical Fellow at Johns Hopkins Oncology Center, became Assistant Professor of Oncology in 1991, and has taught in the School of Medicine ever since. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation, Cellular and Molecular Medicine, and Pathobiology.

Levitsky is a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.  He is a Stohlman Scholar of the Leukemia and Lymphoma Society of America (LLS) and a member of the American Society for Clinical Investigation (ASCI).  He is also an active member of the American Association of Cancer Research, the American Society of Hematology, and is one of a select group of immunologists serving on review panels for both the LLS SCOR program and the Cancer Prevention and Research Institute of Texas. He's a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute's Center for Human Immunology. He's also organized countless tumor immunology meetings.

Levitsky consults on a number of industry scientific advisory boards and he contributes and provides editorial support to several prestigious cancer, immunology, scientific and medical publications. He holds five patents, has mentored 28 medical and PhD students some of whom are now leaders in academia and industry, and is a sought-after speaker at academic and industry conferences.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):